ROS1 and lung carcinoma: Additionally, gilteritinib also displayed potency against ROS1 fusion gene-expressing lung cancer cell lines (HCC78 cells harbor SLC34A2-ROS1 and JFCR-168 harbor CD74-ROS1; Supplementary Fig. 21A, B) and significant tumor regression was observed in vivo (Supplementary Fig. 21C).